MK-8527
Phase 3Small molecule
Merck & Co.MK-8527 is one of 23 small molecule programs targeting Human Immunodeficiency Virus (HIV). It is currently in Phase 3.
2
Indications
16
Total Trials
5
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
23 competitors in Female
#DrugCompanyPhaseTrials
1Activella
Eli LillyPhase 3
Dostarlimab
IncytePhase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Rifadin
SanofiPhase 1
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 1
Versed
CConrado Roberto Hoffmann Filho
Phase 1
Faslodex
FFresenius Kabi USA, LLC
Phase 1
MK-8527
Merck & Co.Phase 3
Protonix
WWyeth-Lederle Vaccines
Phase 1
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Adult3 trials
Human Immunodeficiency Virus (HIV)3 trials
Immunodeficiency1 trial
6 more indications
HIV-1 infection1 trial
Tenofovir Disoproxil Fumarate1 trial
Interaction1 trial
Moderate Hepatic Impairment1 trial
Unspecified2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MK-8527. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company